Ocular Therapeutix (NASDAQ:OCUL) Issues Quarterly Earnings Results

Ocular Therapeutix (NASDAQ:OCUL) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.05), Zacks reports. The company had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%.

Ocular Therapeutix Trading Down 16.9 %

Shares of OCUL opened at $5.93 on Tuesday. The company has a current ratio of 13.01, a quick ratio of 12.94 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $932.30 million, a P/E ratio of -4.49 and a beta of 1.22. The stock’s fifty day simple moving average is $7.84 and its 200 day simple moving average is $8.90. Ocular Therapeutix has a twelve month low of $4.06 and a twelve month high of $11.77.

Insider Buying and Selling

In related news, insider Donald Notman sold 6,301 shares of the stock in a transaction on Friday, January 31st. The stock was sold at an average price of $7.84, for a total value of $49,399.84. Following the completion of the sale, the insider now directly owns 204,563 shares in the company, valued at approximately $1,603,773.92. This represents a 2.99 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Pravin Dugel sold 21,475 shares of the stock in a transaction on Monday, February 24th. The shares were sold at an average price of $6.87, for a total value of $147,533.25. Following the completion of the sale, the insider now owns 3,520,318 shares of the company’s stock, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,895 shares of company stock valued at $283,772. 3.50% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of Ocular Therapeutix in a research report on Tuesday, December 3rd. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $17.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.